Antidotes in the Emergency Department: High-Yield FRCEM SBA Toxicology Questions Explained

Poisoning and self-poisoning account for a substantial proportion of acute medical admissions in the UK, and antidote selection remains one of the highest-stakes clinical decisions an emergency physician makes. It is also a reliably tested domain in the FRCEM SBA exam. Candidates who understand the mechanistic logic behind antidote therapy, rather than memorising isolated drug-antidote pairs, consistently outperform those who do not. This article works through the core antidote scenarios you will encounter in FRCEM SBA toxicology questions, grounding each in pathophysiology, UK guideline evidence, and the precise clinical detail that discriminates a correct answer from a near-miss.

Epidemiology and Clinical Relevance

Self-poisoning is among the top five causes of acute medical admission in England, and paracetamol remains the drug most commonly implicated in both overdose presentations and overdose-related acute liver failure. Opioid-related deaths continue to rise, driven by illicit fentanyl analogues and prescribed opioid analgesics. Carbon monoxide remains the commonest cause of fatal poisoning in the UK, frequently arising from faulty domestic gas appliances and from deliberate self-harm. Benzodiazepine co-ingestion is documented in a significant proportion of fatal overdoses, underlining the clinical importance of recognising mixed toxidromes.

Beyond these headline agents, UK emergency departments regularly manage intentional and accidental overdose with beta-blockers, calcium channel blockers, tricyclic antidepressants (TCAs), digoxin, organophosphates, methanol, ethylene glycol, anticoagulants, insulin, sulphonylureas, cyanide, and iron. Each carries specific antidote therapy with defined indications, doses, and contraindications. The British National Formulary and TOXBASE via the National Poisons Information Service (NPIS) are the primary UK references for dosing and management guidance and should be consulted for all but the most routine cases.

Pathophysiology: Toxidromes and Their Mechanistic Basis

A toxidrome is a recognisable constellation of signs and symptoms produced by a class of poison acting on a defined receptor system or biochemical pathway. The examination frequently presents a clinical vignette and asks you to identify the toxidrome before naming the antidote. Understanding the mechanism makes this deductive rather than purely recall-dependent.

Opioid Toxidrome

Opioids act at mu, kappa, and delta receptors throughout the central and peripheral nervous system. Mu receptor activation in the brainstem produces respiratory depression, miosis, and reduced consciousness. The classic triad is miosis, CNS depression, and respiratory depression. Bradycardia and hypotension reflect both central and peripheral effects. The antidote, naloxone, is a competitive antagonist at all opioid receptor subtypes. Its half-life of 60 to 90 minutes is considerably shorter than most clinically encountered opioids, including methadone (half-life 24 to 36 hours) and modified-release preparations, making re-sedation a genuine clinical risk.

Cholinergic (Organophosphate) Toxidrome

Organophosphates and carbamates irreversibly (or reversibly) inhibit acetylcholinesterase, leading to accumulation of acetylcholine at both muscarinic and nicotinic synapses. Muscarinic features are summarised by the SLUDGE mnemonic: salivation, lacrimation, urination, defaecation, GI distress, and emesis, alongside bradycardia, bronchospasm, and miosis. Nicotinic features at the neuromuscular junction produce fasciculations, weakness, and eventually paralysis. CNS features include agitation, seizures, and coma. Atropine competitively antagonises muscarinic receptors and is titrated to bronchosecretion control (drying of secretions and improvement in oxygenation) rather than heart rate alone. Pralidoxime reactivates acetylcholinesterase and addresses nicotinic features, but is only effective before irreversible ageing of the enzyme-organophosphate complex, which can occur within hours of exposure.

Paracetamol Hepatotoxicity

At therapeutic doses, paracetamol is conjugated with sulphate and glucuronide. In overdose, these pathways are saturated and a greater fraction undergoes CYP2E1-mediated oxidation to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). NAPQI depletes hepatic glutathione and binds covalently to hepatocyte proteins, producing centrilobular necrosis. NAC replenishes glutathione and provides alternative substrates for NAPQI conjugation. It is most effective within eight hours of ingestion but confers benefit up to 24 hours and beyond in some cases. The Rumack-Matthew nomogram, applied to plasma paracetamol concentration plotted against time from ingestion, determines antidote indications in the UK, with a treatment line at 100 mg/L at four hours.

Tricyclic Antidepressant Toxicity

TCAs block fast sodium channels in the myocardium, producing QRS prolongation and ventricular arrhythmias. They also antagonise muscarinic receptors (producing an antimuscarinic toxidrome: dry mouth, urinary retention, mydriasis, tachycardia, reduced bowel sounds) and block alpha-1 adrenoceptors causing vasodilation and hypotension. Sodium bicarbonate is the mainstay of treatment for cardiovascular toxicity; alkalinisation reduces free TCA binding to sodium channels, while the sodium load directly competes with the channel blockade. A QRS duration exceeding 100 ms or a terminal R wave in aVR exceeding 3 mm should prompt bicarbonate administration.

ED Assessment and Management

Every poisoning presentation warrants a structured approach: a focused toxicological history (timing, quantity, formulation, coingestants, access to medications in the household), examination mapped to the major toxidromes, and targeted investigations. Core investigations include 12-lead ECG, blood glucose, venous blood gas with lactate, renal and liver function, a paracetamol level at four hours (or on arrival if more than four hours have elapsed), salicylate level, and ethanol level. Further investigations (digoxin level, carboxyhaemoglobin, methanol level, iron level) are guided by the clinical picture.

TOXBASE should be accessed for every case where the ingested agent is identified, and the NPIS telephone line (0344 892 0111) is available when TOXBASE guidance is insufficient or the clinical situation is complex. The National Institute for Health and Care Excellence has published guidance on self-harm assessment and management that is relevant to the broader clinical context, and the Resuscitation Council UK provides guidance on cardiac arrest in special circumstances including poisoning.

Key Antidote Reference Table

The following high-yield antidote pairings are consistently represented in FRCEM SBA toxicology questions:

• Paracetamol: N-acetylcysteine intravenously; three-bag regimen per current UK protocol (200 mg/kg over 4 hours, then 100 mg/kg over 8 hours, then 200 mg/kg over 16 hours). Anaphylactoid reactions occur in approximately 15% of patients and are managed by temporarily stopping the infusion and administering antihistamines, not by permanent discontinuation.
• Opioids: Naloxone IV, IM, or intranasal; titrate to adequate respiratory effort, not full reversal of analgesia. Consider infusion (two-thirds of the reversal dose per hour) for long-acting opioids.
• Organophosphates: Atropine IV in large titrated doses (starting at 2 to 4 mg, doubling every 5 to 10 minutes until secretions dry); pralidoxime IV for nicotinic features.
• Benzodiazepines: Supportive care is preferred. Flumazenil is contraindicated in dependence, mixed TCA overdose, and epilepsy. Its role is largely limited to reversing procedural sedation.
• Beta-blockers: High-dose insulin euglycaemic therapy (HIET) is now considered first-line for haemodynamically significant toxicity; glucagon is an alternative but supply is limited. Calcium and atropine have limited efficacy.
• Calcium channel blockers: HIET is first-line; intravenous calcium (chloride or gluconate) supports inotropy. Lipid emulsion therapy may be considered for refractory cases per TOXBASE guidance.
• Digoxin: Digoxin-specific antibody fragments (digoxin-specific Fab, Digibind or DigiFab) for life-threatening arrhythmias or potassium above 5.5 mmol/L in acute overdose.
• Carbon monoxide: High-flow 100% oxygen via non-rebreathe mask; hyperbaric oxygen in selected cases (loss of consciousness, neurological signs, pregnancy, carboxyhaemoglobin above 25%).
• Methanol/Ethylene glycol: Fomepizole (alcohol dehydrogenase inhibitor) is first-line; ethanol is an alternative where fomepizole is unavailable. Haemodialysis for severe acidosis or high concentrations.
• Cyanide: Hydroxocobalamin IV (first-line in smoke inhalation/cyanide toxicity in the UK); dicobalt edetate is reserved for confirmed cyanide poisoning in those not responding to hydroxocobalamin.
• Iron: Desferrioxamine IV for significant iron poisoning (metabolic acidosis, serum iron exceeding 90 micromol/L, or symptomatic toxicity).
• Warfarin: Vitamin K and prothrombin complex concentrate (PCC) for life-threatening bleeding; four-factor PCC (Beriplex, Octaplex) is preferred over fresh frozen plasma.
• Dystonic reactions: Procyclidine IV or IM, or benzatropine; the reaction is caused by dopamine D2 antagonism from antipsychotics or antiemetics including metoclopramide and prochlorperazine.

How the FRCEM SBA Exam Tests Toxicology

The FRCEM SBA exam maps to the RCEM curriculum, which includes toxicology as a core knowledge domain. Antidote questions appear regularly and are constructed to test precision rather than broad recall. The most common stem structures are as follows.

First, a vignette describing a toxidrome without naming the drug, asking you to identify the antidote. The discriminator is accurate toxidrome recognition, particularly distinguishing cholinergic from opioid toxidromes (both cause miosis and reduced consciousness, but cholinergic adds bronchospasm, secretions, and bradycardia; opioid toxicity produces pure respiratory depression without the secretory features).

Second, a question about a contraindication or caveat. Flumazenil questions almost always hinge on a contraindication: TCA co-ingestion, benzodiazepine dependence, or a history of epilepsy. NAC questions frequently test the anaphylactoid reaction management (stop infusion, antihistamines, restart at a lower rate) rather than the dosing regimen itself.

Third, a question about timing or monitoring endpoints. Pralidoxime questions test knowledge that its efficacy is time-dependent. Atropine questions test that the endpoint is drying of secretions rather than a specific heart rate. Naloxone questions test awareness of re-sedation risk with long-acting opioids.

The Royal College of Emergency Medicine publishes the FRCEM curriculum, and toxicology appears under acute presentations requiring senior decision-making. Reviewing the curriculum alongside FRCEM SBA practice questions allows you to identify which antidotes carry the highest item frequency.

Revision Pearls: High-Yield Facts

1. The paracetamol nomogram treatment threshold in the UK is 100 mg/L at four hours; the previous high-risk line at 50 mg/L has been removed from the standard protocol.
2. Naloxone’s duration of action (60 to 90 minutes) is shorter than methadone’s half-life (up to 36 hours); patients who respond to naloxone require a minimum of four to six hours of monitored observation.
3. Atropine in organophosphate poisoning may require enormous cumulative doses (tens or even hundreds of milligrams) in severe poisoning; do not under-dose through fear of atropine toxicity.
4. Flumazenil is relatively contraindicated in mixed overdose with TCAs because benzodiazepines are often suppressing seizure activity driven by TCA sodium channel blockade; reversal can precipitate refractory status epilepticus.
5. Digoxin-specific Fab fragments bind free digoxin, rendering the free digoxin assay unreliable post-administration; subsequent digoxin levels do not reflect clinical toxicity.
6. In beta-blocker overdose, HIET works by shifting myocardial metabolism from free fatty acids to glucose, improving inotropy independently of adrenergic receptor binding; it requires concurrent 50% glucose infusion and close monitoring for hypokalaemia.
7. Hydroxocobalamin is the preferred cyanide antidote in the UK for smoke inhalation victims because, unlike dicobalt edetate, it is safe to administer empirically without confirmed cyanide exposure.
8. Ethylene glycol produces an elevated osmolar gap early and an elevated anion gap metabolic acidosis later, as toxic metabolites (oxalate, glycolate) accumulate; urinalysis may show calcium oxalate crystals.

Common Pitfalls: Where Candidates Lose Marks

• Confusing the muscarinic and nicotinic features of organophosphate poisoning: atropine addresses only muscarinic features and has no effect on the paralysis caused by nicotinic receptor activation at the neuromuscular junction.
• Applying the paracetamol nomogram to staggered or unknown time overdoses: the nomogram is only valid for single acute ingestions with a known time. Staggered overdose requires specialist NPIS guidance.
• Administering flumazenil to a patient with an unrecognised TCA co-ingestion or benzodiazepine dependence.
• Stopping naloxone after initial reversal and discharging a patient who has ingested a modified-release or long-acting opioid.
• Under-dosing atropine in organophosphate poisoning by targeting heart rate rather than secretory control.
• Failing to recognise that digoxin Fab administration invalidates subsequent plasma digoxin levels.
• Selecting dicobalt edetate empirically in suspected cyanide poisoning from smoke inhalation, when hydroxocobalamin is the safer first-line agent.

How EM Learning Centre Supports Your MRCEM Single Best Answer Revision

FRCEM SBA toxicology questions reward candidates who understand mechanisms and contraindications rather than those who have simply memorised antidote lists. Developing that depth of understanding requires exposure to well-constructed clinical scenarios that mirror the actual exam format.

The MRCEM Single Best Answer revision course at EM Learning Centre provides a structured, curriculum-mapped question bank covering toxicology alongside all other major ED domains, with detailed answer explanations written at consultant level. Each explanation identifies why the correct answer is correct and, critically, why the distractors are wrong, which is where exam performance is actually won or lost.

Whether you are approaching your first sitting or looking to consolidate before a resit, the EM Learning Centre platform is designed around the specific demands of the MRCEM and FRCEM SBA exams, with content that reflects current UK guidelines, RCEM curriculum mapping, and the clinical realities of UK emergency practice. Toxicology, antidote pharmacology, and poisoning management are covered in depth, with scenario-based questions that replicate the complexity and precision required on exam day.

References

1. Royal College of Emergency Medicine. FRCEM Curriculum and Assessment. Available at: rcem.ac.uk
2. National Institute for Health and Care Excellence. Self-harm: assessment, management and preventing recurrence (NG225). 2022. Available at: nice.org.uk
3. British National Formulary. Poisoning: emergency treatment; specific antidotes. Available at: bnf.nice.org.uk
4. Resuscitation Council UK. Special circumstances: poisoning. Advanced Life Support Guidelines. Available at: resus.org.uk
5. Bateman DN, Dear JW, Thanacoody HKR, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. The Lancet. 2014;383(9918):697-704. Summary available at: bmj.com